Scarica l'app Stockscreener
0.5842
5.41%
-0.0334
Aprea Therapeutics Inc Borsa (APRE) Ultime notizie
Aprea Therapeutics to Present at October Conferences - The Manila Times
Aprea Therapeutics, Inc. (APRE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Aprea Puts Cancer Drug Pipeline Before Investors - MyChesCo
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
Dose Escalation, Combination Strategy Keep Aprea Ahead In Its Oncology Trials - Clinical Leader
Aprea Therapeutics Inc (APRE:UR): Stock Price, Quote and News - bnnbloomberg.ca
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs - marketscreener.com
Aprea Therapeutics Expands Patent Portfolio for Precision Oncology Programs - minichart.com.sg
Aprea Therapeutics reports patent portfolio of 58 patents - Investing.com
Aprea Therapeutics reports patent portfolio of 58 patents By Investing.com - Investing.com Canada
Aprea Therapeutics reports patent portfolio of 58 patents By Investing.com - Investing.com India
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs - manilatimes.net
Aprea Therapeutics reports patent portfolio of 58 patents By Investing.com - Investing.com UK
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs - marketscreener.com
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs - Barchart.com
Aprea Therapeutics records second consecutive surge, jumping another 22% (APRE:NASDAQ) - Seeking Alpha
Aprea (APRE) Q1 2026 Earnings: EPS Prints Above Forecast in the Latest Session; Trading Move: The Stock Gains 1.19% in the Current UpdateEarnings Expansion Phase - vinanet.vn
Aprea (APRE) Stock: Advances 1.19% to $0.64 in the Latest Reading; Market Levels: the Current Price Sits Inside the Supplied Technical Range in the Current UpdateHigh Volume Node - vinanet.vn
Aprea (APRE) Q1 2026 Earnings: EPS Prints Above Forecast in the Latest Session; Trading Move: The Stock Gains 1.19% in the Current UpdateOne-Time Loss Impact - careplusvn.com
Aprea (APRE) Q1 2026 Earnings: EPS Prints Above Forecast in the Latest Session; Trading Move: The Stock Gains 1.19% in the Current UpdateEarnings Weakness Phase - dars.gov.et
Aprea (APRE) Q1 2026 Scorecard: EPS Exceeds Its Estimate in the Latest Session; Stock Move: The Market Price Declines 2.61% at the CloseInterim Report - careplusvn.com
Aprea (APRE) Technical Snapshot: Slides 2.03% to $0.68 for the Current Session; Session Range View: Price Remains Between $0.65 Support and $0.71 Resistance under the Current SnapshotChandelier Stop - vinanet.vn
Aprea (APRE) Technical Snapshot: Slides 2.03% to $0.68 for the Current Session; Session Range View: Price Remains Between $0.65 Support and $0.71 Resistance under the Current SnapshotLow Risk Entry Stocks - dars.gov.et
APRE Q1 2026 Earnings: Narrower-than-Expected Loss Signals Disciplined ExecutionEarnings Recovery Stocks - Vinanet
Aprea Expands Cancer Trial as APR-1051 Shows Early Activity - MyChesCo
Aprea Therapeutics (APRE) Edges Higher by 1.34% as Shares Hover Above Key SupportStrangle Setup - vinanet.vn
Maxim Group Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Aprea Therapeutics (APRE) Consolidates Near Support as Shares Dip 1.76%Mid Cap Momentum - vinanet.vn
Oppenheimer Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Aprea Therapeutics (APRE) Consolidates Near Support as Shares Dip 1.76%Quote Data - dars.gov.et
Aprea Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Aprea Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Aprea Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Aprea Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
APRE: APR-1051 demonstrates promising early efficacy and safety, driving a biomarker-focused oncology pipeline - TradingView
Aprea Therapeutics advances APR-1051 oncology pipeline progress - TipRanks
Form 8K Aprea Therapeutics Inc For: 12 August - Investing.com India
Aprea Therapeutics 2Q 2026: Revenue $0 Net loss $(3.59M), EPS $(0.07) — 10-Q Summary - TradingView
Form 8K Aprea Therapeutics Inc For: 12 August By Investing.com - Investing.com Canada
Aprea Therapeutics (NASDAQ: APRE) extends cash runway with $41M balance and trial updates - Stock Titan
Aprea Therapeutics Announces Second Quarter 2026 Financial Results - The Manila Times
Aprea Therapeutics Reports $3.6 Million Q2 Net Loss - Quiver Quantitative
Aprea Therapeutics Q2 net loss widens on higher R&D costs - TradingView
Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001 - finance.yahoo.com
Price to earnings forward of Aprea Therapeutics, Inc. – NASDAQ:APRE - TradingView
Aprea Therapeutics Inc (APRE) Stock News Today - TradingKey
Aprea Therapeutics Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Aprea Therapeutics, Inc. (APRE) stock price, news, quote and history - Yahoo Finance Singapore
Aprea Therapeutics Inc (APRE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aprea Expands APR-1051 Trial as Enrollment Accelerates - mychesco.com
4.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):